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Narcotics and Cancer Pain Control
by C. Stratton Hill, Jr., M.D.
Director) Pain Service
Department of Neuro-Oncowgy

In the past two decades, improved cancer treatment has
caused more patients to be
cured and brought longer survival to those not cured. Nevertheless, a significant number
remain ill, troubled by a wide
variety of symptoms as the disease progresses. Pain, nausea
and vomiting, anorexia, weakC. Stratton Hill, Jr.
ness, insomnia, and failure to
thrive are the most important; of this group, pain is probably the outstanding symptom, the one patients dread
most. As the tumor grows and spreads, the pain becomes
diffuse. Most likely, the pain originates from several
sources, and removing the cause is impossible, making
systemic analgesics the mainstay of treatment for this
type of pain.
At the same time, however, our understanding of pain
has grown. We have found the opiate (narcotic) binding
sites in the central nervous system and the naturally occurring ligands for these binding sites. We know the mechanisms of spinal cord modulation of pain, and we have a better understanding of neuropathic and deafferentation pains
and central pain states. We know that some pains are partially or totally unresponsive to opiates and are developing
drugs for binding at specific opiate-binding sites; we hope
that these drugs will have fewer of the undesirable side effects of the opiates. In other words, we have learned that
there is more to pain treatment than saturating the opiatebinding sites of the central nervous system with opiates.
In spite of progress in both fields, patients with cancer
may suffer pain of such severity that they will require narcotic analgesics to control it. Although physicians recog-

nize the effectiveness of narcotics as pain relievers, the
medical literature reports increasing numbers of cancer
patients whose pain is unrelieved. What, then, is the problem? Are there barriers to the effective use of narcotics? If
so, what are they? What can be done to break them down
or overcome them? At M. D. Anderson, the Pain Service is
available to advise physicians on ways to achieve optimum
pain control for their patients.

The Nature of Pain
The first important concept bearing on narcotic use is the
physician's idea of what pain is. In our culture, pain is perceived as a symptom that must have a biomedical explanation. If this biomedical modeffails, that is, if a patient complains of pain for which no cause can be found, then the
pain, we decide, is psychological. To some physicians this
means the pain is imaginary, and they are extremely reluctant to give narcotics to patients complaining of such pain.
Occasionally, the biomedical model fails in cancer patients
with pain. I know of several patients with severe pain who
were denied narcotics when their pain was indeed responsive to such drugs. We should make every effort to identify
the etiology of a pain and attack the cause if possible, but if
detecting the source is beyond the capabilities of the diagnostic instrument, adequate treatment should be given
anyway, including the use of narcotics. In most cases, this
pain will prove to be of nociceptive origin.
Understanding pain is important also in deciding when
not to use narcotics or when to limit their use for pain control. In some patients, pain is not relieved by narcotics
because the patients have become tolerant to the dosage
prescribed. In such cases, simply increasing the dose of narcotic will solve the problem. Some types of pain, however,
are totally or partially unresponsive to narcotics. These
pains may be grouped into (1) central pain states, such as
post-herpetic neuralgia, phantom limb pain, and causalgia;
(2) narcotic unresponsive pain, such as muscle spasm, dysesthesia, "tenesmoid" sensations of the rectum and blad-
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tory depression is rare to nonexistent in patients tolerant to
narcotics. By the same token, respiratory depression in the
nontolerant patient with severe pain is unlikely as long as
the pain is unrelieved. That is why a narcotic-naive patient
with intense pain, such as that seen in renal stone colic or
sickle-cell crisis, can tolerate an extremely high dose of narcotic. A physician should give whatever dose is required to
relieve the pain.

der seen after radiation therapy, reflex sympathetic dystrophy, and bone pain; and (3) pain that is actually physical
and mental suffering, a complex experience associated with
the negative emotions that almost always accompany
chronic pain . The patient's suffering may have become so
overwhelming that he or she describes any experience as
"pain." Narcotics prescribed in this latter circumstance
will almost never work and may indeed cause more dysphoria, making the patient worse.

For Chronic Pain, Oral Medication
Chronic pain is best treated with oral medication because
it allows the patient more mobility and participation in
daily life . Other routes of administration-intramuscular
injection, intravenous infusion, rectal suppository, or indwelling reservoirs-should be used only if the oral route
is not available, that is, if the patient has problems such as
intestinal obstruction or nausea and vomiting secondary to
chemotherapy. Yet physicians often perceive the parenteral
route as more effective and choose it instead of the oral
route because it is actually an increase in the dose given.
Physicians either were not taught or have forgotten the
"first pass" effect through the liver-biotransformationwhen drugs are given by mouth.
Biotransformation inactivates about two-thirds of the
oral dose of morphine. To overcome this phenomenon, the
oral dose must be three times larger than the parenteral
dose . The ultimate dose reaching the opiate-binding sites
of the central nervous system, however, will be essentially
the same as the parenteral dose. Exactly the same results
can be achieved with both oral and parenteral doses of narcotics if one allows for biotransformation. The accompanying table lists oral-to-parenteral ratios for commonly used
narcotics that are equianalgesic to 10 mg of morphine
given parenterally for severe pain.

Oral Doses of Narcotic Analgesics
That Achieve the Same Pain Relief
as l Omg Parenteral Morphine

for Severe Pain

Drug

Oral Dose

Oral-to-Parenteral
Dose Ratio

Parenteral
Dose

Morphine
(single dose)
(repeated dose)

60mg
30mg

6:1
3: 1

10mg
10mg

Hydromorphone
(Dilaudid)

7.5mg

5: 1

l.5 mg

Methadone

20mg

2: 1

10mg

Levorphan

4mg

2:1

2 mg

Meperidine
(Demerol)

300mg

4: l

75 mg

Codeine

200mg

l.5: 1

130mg

Effects on Respiration R ate
Other pharmacologic barriers to effective narcotic use are
related to misconceptions about respiratory depression and
the addictive potential of narcotics . In considering respiratory depression, we must separate narcotic-naive patients
from the narcotic-tolerant. Pain is a natural antagonist to
the action of opiates-the stronger the pain, the more opiate is required to relieve it. This accounts for the lack of
ceiling effect for the dose of opiate: an effect is achieved
with all significant increases in dosage. A common question about narcotics among lay persons is, ''What will I do
when the pain gets really bad?" The answer is simple:
"Increase the dose."
Patients who become tolerant to the analgesic effect of
narcotics have also grown tolerant to their respiratory
depressant effect-as the dose is increased to relieve the
pain, the more it takes to depress the respiration. Respira-

Dependency Versus Addiction
One of the most misunderstood aspects of narcotic
analgesic use is their addictive potential. Basically, the
problem is confusion about the definitions of dependency
and addiction . Dependency simply means a person needs
the drug to prevent distressing symptoms secondary to the
absence of the drug, the so-called "withdrawal" or "abstinence" reaction. This is essentially a medical definition,
with medical determinants. A person may be dependent
and not addicted; these terms should not be used
interchangeably.
Addiction has no medical determinants, only social ones.
Addicts devote all their lives to the drug they must have,
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sacrificing everything they value, including reputation and
financial, social, and political resources. Addicts give up
their enjoyment of family, food, sex, and personal freedom; they even give up life itself to the drug in questiont heir major activities are procuring and taking drugs.
Fortunately, few people turn over their lives to drugs in
this fashion, especially if their introduction to the drug
comes through medical channels. It is therefore unlikely
that a cancer patient in pain will eventually become a street
addict. Unfortunately, many physicians fear such an outcome if patients are exposed to chemicals with potentially
euphorigenic qualities for a long enough time. Physicians
seem to ignore the facts that patients may have strong
moral values they have been committed to all their lives.
They may have made significant contributions to the communities in which they live. Cancer patients taking narcotics seldom are euphoric; if they do experience euphoria
occasionally, it is unlikely this experience will be so overwhelming that it will cause them to abandon all values
previously held.

are the attitudes of the family, friends, and patients themselves towards narcotics. All these groups fear addiction,
which they consider synonymous with drug abuse and all
its negative connotations. Somehow the notion is abroad
that, when a patient is given a drug with mood-altering
properties, any degree of euphoria the drug produces will
create an overpowering craving for the drug, and the patient's entire value system will be destroyed. That is not
true. I have continually observed that patients who take
narcotics for pain control simply stop taking the drug
when the pain is relieved. Numerous studies support
this observation.

Uncertainty About Drug Laws
A final barrier to narcotic use is physician uncertainty
about state and federal laws and regulations relating to narcotics and how those laws are enforced. Most physicians are
unaware of the contents of these laws and regulations,
which often contain ambiguous language that fails to distinguish a drug abuser from someone taking the same drug
for legitimate medical needs. Until the laws are changed,
this problem will persist.
One result of this uncertainty is a practice called "stacking," in which the physician. prescribes an additional narcotic with the same mechanism of action when the pain
cannot be controlled by the first drug. For example, when
hydromorphone (Dilaudid)-taken in a dose of8 mg every
three hours around the dock-cannot control the pain,
the physician adds another narcotic such as morphine
rather than increase the hydromorphone dose beyond the
"usual" dose range. This practice may proceed to include
several other drugs, until the patient is taking numerous
drugs at various time intervals and becomes confused about
what should be taken and when. Prescribing one drug at
adequate doses and with a single, scheduled time interval
is preferable, because it is easier for the patient. Fear of
attracting the attention of regulatory agencies prevents
physicians from pursuing the latter course.

Prescribing by Custom
Medical school pharmacology courses usually provide
adequate and accurate information about the action of narcot ics. One problem frequently seen, however, ·can be attributed either to a physician's memory lapse or to "customary prescribing.''
T hose ofus who study pain treatment find that physicians prescribe narcotics according to custom rather than
pharmacology. John Morgan, M.D., of the department of
pharmacology of the City University of New York Medical
School, compared what students were taught about narcotics in his pharmacology courses with how they actually prescribed narcotics for pain relief. When tested on the dosage
and duration of action of various narcotics, students passed
the examination without difficulty. But when their subsequent hospital performance in actually prescribing narcotics was evaluated several years later, Morgan found that
they prescribed according to custom, even though it contradicted what they had been taught about the pharmacology of the drug. The dosage prescribed was less than the
recommended amount, and the time between doses was
usually longer tnan tne known duration of action of
the drug.
It is customary to undertreat all pain, and cancer pain
is no exception. Morgan suggested that physicians have
developed an "opiophobia" that prevents prescribing opiates in adequate doses. This phobia is like all others-not
subject to rational correction. He suggested that educational efforts be directed to the cultural attitudes of our
society, since it is unlikely that adequate doses of narcotics
will be prescribed for patients until the phobia is
dealt with.
Other cultural influences on narcotic use for pain control

Patients Are Not Street Addicts
Cancer pain control is not likely to improve until these
cultural issues are addressed and correct:ea.tducat:iona
efforts must be directed to all segments of society. Both
professional and lay persons must be taught that cancer
pain can be controlled, in the vast majority of cases, with
the means currently available to most physicians. The beneficial nature of the legitimate use of narcotics must be
emphasized. There is no doubt that we have a prodigious
drug abuse problem with narcotics in this country. Physicians do not want to contribute to this problem, but there
is little evidence that they do. Those that do divert drugs
from legitimate to illegitimate use-"script doctors"-are
continued on page 8
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Shared Research Resources Provide Expertise
and Cost Savings
Researchers preparing grant
applications often consult with
Chan, who may provide scientific and technical input even
at this stage. '' Since developing a monoclonal antibody is a
complicated procedure, I can
usually strengthen their proposal by providing specific
information. IfI collaborate
James C. Chan
on projects, I then write that
part of the grant proposal myself. After the grant is
awarded, in addition to producing the monoclonal antibody, I might suggest how to maximize its production,
purification, and utilization.''
Producing a monoclonal antibody is a complex and tedious process. First, B lymphocytes that have been immunized to produce antibodies against only on·e antigen are
isolated, Chan explained. These cells are then fused with
"immortal" myeloma cells, thus producing a hybridoma.
(Cloning of myeloma cells was done about 10 to 15 years
ago. If maintained in proper culture conditions, these cells
live indefinitely.) The hybridoma now contains both immortality and the information to produce a monoclonal
antibody against one antigen. In effect, the hybridoma is a
permanent biologic factory that produces one highly specific antibody, the monoclonal.
Monoclonal antibodies can be used to purify immunotherapeutic agents (such as interferon or growth factors)
and to detect tumor markers and t he sites on viruses that
attach to and ultimately destroy cells. When used with
radioimaging techniques, ·monoclonal antibodies can be
used to study how cancer cells metastasize. In some studies,
monoclonal antibodies have proved to be effective delivery
vehicles for cancer drugs, Chan said.
The number oflaboratories in the United States that will
provide custom-made monoclonal antibodies is limited, according to Chan. Having a hybridoma facility in the institution is an obvious benefit to M. D. · Ande.rson researchersconvenient and two to three times less expensive than
commercial laboratories, Chan said. ' 'Moreover, since we
make the antibodies, if they were to have any commercial
applications, the institution could patent them and retain
exclusive rights to them."
Chan's laboratory collaborated with the late Benjamin
Drewinko, M.D., Ph.D., and his coworker Li-ying Yang,
M.S., of the Department ofLaboratory Medicine. Yang
assisted Drewinko in the development of monoclonal anti-

Studying colon cancer, a scientist may have isolated a particular marker protein, unique to colon cancer cells, that
potentially has diagnostic application. The scientist knows
that raising a monoclonal antibody is the first step toward
the development of a diagnostic assay but is unfamiliar with
the technique. What are his or her alternatives?
Traditionally, researchers depended on commercial biotechnology companies for such specialty procedures, but
now, primarily owing to funding by the National Cancer
Institute (NCI), M. D. Anderson Cancer Center investigators can take advantage of 15 in-house laboratories
equipped to provide essential specialty procedures and
services. Collected under the name Shared Research
Resources, these laboratories develop monoclonal antibodies, synthesize DNA, and perform genetic signature analysis.
In addition, researchers may also recruit laboratory services in antigen synthesis, gene cloning assays, biosafety,
tissue procurement and banking, histopathology, electron
microscopy, cytometry, ·and recombinant DNA. Other
shared resources extend veterinary care for research animals
or provide specialized animal models for research. Still others offer help with biostatistics and computational
resources. These services will be supported through 1992
as a result of a $6. 9 million core grant from the NCI.
The complexity of these services varies, but they all have
one thing in common: each requires specialized knowledge
and specific equipment and materials.
Having these services in-house has several advantages.
They are not only convenient but also less expensive than
those offered by biotechnology companies. Moreover, the
directors of these services, since they routinely use these
procedures themselves in their own research, are in effect
on-the-spot experts who are readily available for
consul tat ion.

Monoclonal Antibodies
A case in point is the Department ofTumor Biology's
Hybridoma Core Facility directed by James C. Chan,
Ph.D. The lab has produced more than 5,000 monoclonal
antibodies during the past 6 years. "We developed an improved procedure for use in our own research," Chan said.
'' As a part of Shared Research Resources, we can offer it
to our M. D. Anderson colleagues to further their research
as well. Shared Research Resources is a neat concept, and
it works."
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bo_dies to detect a tumor marker for colon cancer. "The
monoclonal antibodies were central to our research," Yang
Genetic Signature Analysis
said, ''but we were unfamiliar with the technique. The
Another se_rvice available to Anderson researchers is
input and assistance Dr. Chan's laboratory provided were
genetic signature analysis, a process by which a cell line's
extremely helpful to us. We probably could have had an
identity or purity is established by examining its DNA.
outside company develop the antibody, but in terms of
Michael]. Siciliano, Ph.D.,
convenience and cost, it was clearly more efficient to work
of the Department of Molecuwith Chan."
lar Genetics, directs the Cell
In addition to monoclonal antibodies, Anderson reLine Identification Facility.
searchers can obtain other biologic substances from their
''Cell lines need to be checked
colleagues. Edwin C. Murphy, Jr., Ph.D., of the Departroutinely," he said. "Labs are
ment ofTumor Biology, directs the Macromolecular Synrun not by gods but by people,
thesis Facility. His lab uses a DNA synthesizer to construct
and therefore mistakes are
short stretches of DNA called oligonucleotides.
sometimes made-a tube may
"With a DNA synthesizer, you can quickly construct a
be mislabeled, a cell line crosssite-directed mutant, which essentially is a slightly altered
Michael J. Siciliano
contaminated."
form of a DNA sequence that has already been isolated,"
Siciliano uses two procedures to identify cell lines: isoMurphy said. By manipulating the DNA sequence and
zyme marker analysis and restriction fragment-length polystudying how these altered sequences affect the function
morphism (RFLP) analysis.
of the gene, investigators can learn more about that
For isozyme analysis, Siciliano 's laboratory examines 11
gene's role in carcinogenesis .
proteins called isozymes. Each of these isozymes is genetiMoreover, impediments to standard DNA cloning techcally polymorphic, which means that slightly variant forms
niques can be overcome by synthesizing DNA. "In our
of the proteins may be produced in cell lines from different
lab, for instance, we had some viral DNA that was exsources. The spectrum of variant forms of these isozymes
tremely difficult to clone,"
present in a cell provides that cell line's genetic signature.
Murphy said. "But we did
"We first look at the isozyme marker polymorphisms,
know some things about its
and they usually give us a fairly good identification. If we
structure, so we combined
still cannot definitively determine whe_ther the cells under
some pieces of a related viral
study have the same or independent genetic origins, then
DNA with a synthetic oliwe use RFLP analysis," Siciliano said.
gonucleotide and actually
In RFLP analysis, DNA is divided into numerous fragmade the viral DNA we
ments by restriction enzymes that recognize specific locacouldn't clone. Ifit hadn't
tions along the DNA sequence. The resultant fragments
been for the DNA synthesizer,
are placed on a gel and subjected to an electric field, which
Edwin C. Murphy, Jr.
we would probably still be
causes them to separate into bands according to size. So
wondering how to clone this viral DNA."
that the bands can be visualized, the fragments in the
Oligonucleotides are readily obtainable from biotechnolbands are hybridized, or fused, to a specific radiolabeled
ogy companies. However, Murphy charges two to three
DNA probe. Without mutations, the DNA fragments rectimes less than most biotechnology companies do, and he
ognized by the probe would be identical for every individwill assist researchers who are unfamiliar with the techual. The mutations, however, alter sizes of the fragments
nique. "I will sometimes suggest how long the oligonuthese enzymes produce. These particular fragments prescleotide should be and what part of the gene it should be
ent in each cell line help establish its genetic signature.
taken from, but that depends on the expertise of the reRFLP and isozyme marker analyses, according to
~earchers~ Murphy said. ''Us ~ ~'------------------.S~ilEE;f-JillniaHnl(O:r.,,'._..'-aare-1½-''«»·~8::l-:lrE-te-;~-roffFt_-tffi--1:--t--t=½e--'retc!½fllil~'------------j
me with a description of a sequence and we make it, but
requires a certain amount of sophistication and special supif the oligonucleotide doesn't perform as expected,
plies." These services could be obtained elsewhere, but
I'm always available to troubleshoot."
since Siciliana's services are supported entirely by the NCI
Laurence D. Etkin, Ph.D., of the Department of Moleccore grant, researchers are not charged for cell line identifiular Genetics, uses oligonucleotide probes in his research
cation. Moreover, Siciliano provides an in-depth interprewith mRNA. "Oligonucleotides are an integral part of our
tation of the tests.
assay system. Without them, we would have to use a less
Louise C. Strong, M.D., of the Department ofExperiprecise and much more difficult method," Etkin said.
mental Pediatrics, uses the facility approximately once
"And it's a definite advantage to be able to deal with someevery two weeks. "A major part of our research involves
one directly instead of a private company over the phone.
developing tumors in mice from human tumor cells. It's
Murphy's lab bends over backwards to help."
continued on page 8
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For Non-small Cell Lung Cancer, Combinations of
Surgery, Chemotherapy, and Radiotherapy
for patients with stage II and III NSCLC, in which the
regional lymph nodes are involved; but no carefully controlled studies have been done.
In three research programs on NSCLC, physicians at The
University of Texas M. D. Anderson Cancer Center are
studying the effectiveness of chemotherapy and radiotherapy in addition to surgery for patients who have the disease
at stage II or III. Randomized studies that include control
groups will allow physicians to interpret the resulting data
and determine whether this kind of additional therapy is
helpful. As far as the researchers know, each of the treatment plans being studied is equally effective.
The standard approach to NSCLC is surgical removal of
the tumor, if possible. " But probably only 20% to 30% of
all patients with lung cancer will have operable tumors,"
said Jack Roth, M.D., chairman of the Department of
Thoracic Surgery. '' And of
those patients with NSCLC,
perhaps only 5% or 10% will
ever be cured by surgical treatment. Our goal is somehow to
reduce these patients' risk of
developing metastases, because
in the majority of cases
patients die of metastatic disease.'' Roth hopes that sys.Jack A. Roth
temic therapy, including che-

Lung cancer is the most lethal human cancer in the United
States-the American Cancer Society estimates that
152,000 new cases oflung cancer and 139,000 deaths
from the disease will occur in 1988. Despite all efforts,
the disease resists long-term cure.
Part of the problem is that lung cancer is extremely difficult to detect early and, in advanced stages, difficult to
cure. Symptoms do not appear until the disease is advanced. Because of this, only about one-fourth of all lung
cancers are found in an early stage, when the tumor is still
localized and has not spread to the hilar, bronchopulmonary, or mediastinal lymph nodes or to other organs. Patients with such limited disease have a fair prognosis with surgery; the five-year survival rate ranges from 33% to 50%.
Although there are four different cell types in lung cancer, the disease is usually divided into two groups, based
on the tumor's behavior and response to treatment-small
cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). SCLC is a fast-growing tumor that disseminates
early; it is not responsive to surgery but is generally responsive to irradiation and chemotherapy. In contrast,
NSCLC-which makes up about 70% of all lung cancersis a slow-growing tumor that responds well to surgery in
early stages, but its record of response to irradiation and
chemotherapy has so far been modest. In promising pilot
studies, researchers have used multiple modes of therapysurgery, combination chemotherapy, and radiotherapy-

LUNG CANCER RESEARCH STUDIES
Modes of Treatment
Patient
Profile

Treatment
Plan

Stage 11-111
limited NSCLC
(Complete resection)

Chemoradiotherapy
arm

Complete
resection

Surgery
arm

Complete
resection

Chemoradiotherapy
arm

Partial
resection

Radiotherapy
arm

Partial
resection

Stage 11-111
limited NSCLC
(Incomplete resection)

Stage Illa
NSCLC

Chemotherapy
arm

Preoperative
Chemotherapy

Surgery

CEP

Partial or
complete resection

Surgery arm

Surgical exploration

*CEP : cyclophosphamide, etoposide, cisplatin.
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Postoperative
Chemotherapy

Radiotherapy

CEP*

Chest and brain
irradiation

CEP

Chest and brain
irradiation
Chest
irradiation

CEP

July-September 1988 Vol. 33, No. 3

motherapy and biologic response modifiers, will eventually
be able to control metastases in sites not accessible to radiation, such as the liver, bone, and adrenal gland.
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Combination Chemotherapy

President, The University of Texas M. D. Anderson Cancer Center
Charles A. LeMaistre, M.D.

Finding effective chemotherapeutic agents is part of the
Vice President for Academic Affairs
problem. Earlier studies of chemotherapy, with both single
James M. Bowen, Ph.D.
agents and combination chemotherapy, have been disapAssociate Vice President for Academic Affairs
pointing, possibly because of ineffective agents, inapproRobin R. Sandefur, Ph.D.
priate dose and schedule, or poor study design, according
Director, Deportment of Scientific Publications
to Waun K. Hong, M .D., chief of the Section ofThoracic
Walter J. Pagel
Oncology.
Editor
"The other problem may be in relationship to timing.
Susan O'Brien Wilkinson
Perhaps if the agents are given first, when the metastatic
Contributing Editors
tumor burden is at its lowest level, they might be more
Lore Feldman
effective," continued Roth.
Kevin Flynn
One study includes patients whose tumors were comArt and Photography
pletely resected and who had no regional lymph node inMonica Keogh, Design and Layout
volvement. Patients are selected to receive either postopDonald G. Kelley, Photographs
erative chemotherapy and chest and brain irradiation or
Published quarterly by the Department of Scientific Publications,
no additional treatment.
Division of Academic Affairs, The University of Texas M.. D. Anderson
In a second study, patients whose tumors were partially
Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030.
resected receive either postoperative chemotherapy and
Made possible by a gift from the late Mrs. Harry C. Wiess .
chest and brain irradiation, or postoperative chest irradiation only, to achieve local control.
In the third study, patients with metastasis to mediastinal lymph nodes but no distant metastasis and whose
tumors are resectable or potentially resectable receive
The benefit of postoperative radiotherapy in lung cancer
either pre- and postoperative chemotherapy or immehas not yet been proved. "Some studies demonstrated that
diate surgery and no chemotherapy (see table).
local control was greatly in"Using combination chemotherapy as an adjunct treatcreased but survival was not,"
ment is a fairly new approach to treating non-small cell
said Ellerbroek. "I still
lung cancer," said Hong. In all
think that local control is a
three studies, patients on cheworthy goal, one worth five
motherapy receive six courses
weeks of treatment. But I also
of cyclophosphamide, etopothink it's exciting to be able to
side, and cisplatin. This regiquantitate what benefit this
men was chosen because of the
will be to patients, rather than
extensive experience at M. D.
just guessing," she continued.
Anderson with these drugs in
· Nancy A. Ellerbroek
Physicians estimate that
non-small cell lung cancer,
there are 120,000 new cases of non-small cell lung cancer
because the drugs are welleach year. If these new treatments have even a small effect,
- - ---Wuonttlorig
tolerated-+b*)H'pf--¥a,Ht=-t,ie~nF-+1tl-c'.s~, -;.i-ant+dl-+--- - - --------¼t---1-lh1-te---1-t-t-10'hta,Hl---1-nuuum+l-t---Jb.~ ~ ~
because the response rate (42%) in a study of these drugs
very large.
chaired by Theera Umsawasdi, M.D., is the highest
''This institution is unique in its ability to do these studreported.
ies, with the expertise and the numbers of patients necessary. Because of that, I believe that we have an obligation
to conduct well-designed clinical trials," Roth
concluded.
■
Postoperative Radiotherapy
After completing their chemotherapy, patients undergo
five to six and a half weeks of radiotherapy to the chest to
prevent local recurrence and brain irradiation to prevent
the appearance of brain metastasis, said Nancy Ellerbroek,
M.D., a radiotherapist working in the program.

Physicians who desire additional information may write Jack A. Roth,
M.D., Department ofThoracic Surgery, Box 109, or Waun K. Hong,
M.D., Department of Medical Oncology, Box 80, The University of
Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard,
Houston, Texas 77030, or call (713) 792-6932, Roth; 792-3039, Hong.

7

DO'J03NQ
S/Uf.4,i /11:J!UU:J A31UV:J i1un7
S3::U1WS3}[ qJ.4,113S3}1 P3,,,tVqS

U!Vd A,3JUV:J puv S3!,1-0J,,,tVN
-31tSS! S!q1-

paisanba-J uoi+:>aJJOJ ssaJppv

soxa1 'u,isnv
l ·oN +!WJad
Ol\fd
a6D+S0d ·s·n
·6JQ +!}OJdUON

Narcotics and Cancer Pain

UJ

0£0LL soxa1 'UO+SOOH
pJ0Aa1nog aqwoJIOH SLS L
JaiuaJ JaJuoJ uosJapuv ·a ·wrn
r£l 8WH 'SUO!+DJ!lqnd J!muaps }O iuaw+Jodaa

Shared Research Resources continued from page s

continued from page 3

criminals and should be sought out and prosecuted. Fortunately, this group represents a very small number. Drug
abuse should not prevent the physician from prescribing
or the patient from using narcotics for pain control.
Unfortunately, the current "Just Say No" campaign
emphasizes only the negative aspects of drug use. No mention is made of the positive uses of these drugs. As a result
of this campaign, it will be even more difficult for physicians to buck the trend and prescribe more narcotics or prescribe them differently or for patients to accept narcotic
use. Moreover, the physician must fulfill his obligation to
relieve pain in spite of it. One negative habit health care
professionals must break is the tendency to treat unrelieved
cancer pain patients like street addicts when they request
better pain relief with narcotics .
Breaking down the other barriers I have discussed here
may require multiple smallaiscrrssion groups at the community level to separate fact from myth about narcotics
and their use. ■

important for us to insure that the tumors that de elop did
so from the tumor cells that were injected," she said.
"Otherwise, we could waste six months to a year stud ing
a tumor that's irrelevant to our research. We could send
these outside, but, in addition to the expense, th r is an
increased likelihood of cross-contamination with oth r cell
lines. It's very helpful to have this service in-house.
According to Anthony J. Mastromarino, Ph.D. assistant vice president for research, the Shared Research
Resources indeed help individual researchers, but th
benefits are much broader.
"Access is critical," he said. "Given the size of the institution, some of these researchers might never meet ere it
not for the interaction promoted by these facilities. This
interlaboratory communication often leads to collaborati e
efforts. Even when direct collaboration doesn't result, the informal consultation that goes on usually gi es the individual re~earcher ideas for his own research. As a result, the research at M. D.. Anderson is, as a whole, much better for it. ' ■

Physicians who desire additional information may write C. Stratton
Hill, Jr., M.D., Pain Service, Box 8, The University ofTexas M. D.
Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas
77030, or call (713) 792-2824.

Physicians who desire additional information ma \ rite Anthon J.
Mastromarino, Ph.D., Office of the Vice President for Research Box
101, The University ofTexas M . D. Anderson Cancer Center 1515
Holcombe Boulevard, Houston, Texas 77030 or call (713) 792-3391.

8

